Apoxis SA, a Swiss biopharmaceutical company developing oncology and immunology products, today announced it has received Orphan Medicinal Product designation from the FDA for its rare disease protein therapeutic, APO200.
Apoxis SA, a Swiss biopharmaceutical company developing oncology and immunology products, today announced it has received Orphan Medicinal Product designation from the FDA for its rare disease protein therapeutic, APO200.
